A biopsy is the removal of a small sample of tissue or cells from the body so a pathologist can examine it under a microscope, run molecular tests, or both. It remains the single most reliable way to confirm whether a lump is cancerous, determine why a transplanted organ is failing, or identify infections that blood tests alone cannot pin down. The word covers a surprisingly wide range of procedures, from a quick needle stick in a doctor’s office to a surgical excision performed under general anesthesia, and the type of biopsy chosen can shape everything from diagnostic accuracy to recovery time.
How Tissue Is Collected
The three most common biopsy methods differ in the size of the sample they retrieve and the amount of information a pathologist can extract from it. Fine-needle aspiration (FNA) uses a thin needle to suction out individual cells or tiny clusters. Core needle biopsy uses a slightly larger, hollow needle to pull out a cylinder of intact tissue. And excisional or incisional biopsy involves surgically cutting out part or all of a suspicious area.
FNA is fast, minimally invasive, and often requires no anesthesia beyond a surface numbing agent. But because it captures loose cells rather than a structured piece of tissue, it gives pathologists less architectural detail to work with. A head-to-head study of soft-tissue masses found that FNA and core biopsy had similar sensitivity for detecting malignancy, around 79% each, but core biopsy pulled ahead on specificity and was more accurate at identifying the exact tumor type and guiding treatment decisions.
The gap widens in certain organs. A meta-analysis of salivary gland tumors found core needle biopsy had a sensitivity near 99%, compared with roughly 68% for FNA, while specificity remained high for both. FNA also produced more non-diagnostic samples that had to be repeated.
In practice, doctors often start with the least invasive option and escalate if needed. A fine-needle aspirate that comes back inconclusive may be followed by a core biopsy, and a core biopsy that cannot rule out a diagnosis may lead to a surgical biopsy. The goal is always to get a definitive answer with the smallest amount of tissue removal.
Why Biopsy Type Matters for Melanoma
Skin biopsies illustrate how much the sampling technique itself can affect outcomes. Clinical guidelines for suspected melanoma recommend a full-thickness excision biopsy whenever possible, because the pathologist needs to measure the tumor’s depth (known as Breslow thickness) to stage the cancer and plan treatment. Punch biopsies, shave biopsies, and partial incisions can miss the deepest part of the lesion, potentially understaging it.
A systematic review and meta-analysis found a statistically higher all-cause mortality in patients whose melanoma was initially sampled with a punch biopsy compared to excisional biopsy. The authors noted the difference was likely influenced by demographic variation and small sample sizes rather than the biopsy itself causing worse outcomes, and the finding did not reach significance for melanoma-specific mortality. Still, the data reinforce why guidelines favor excisional biopsy: getting the full picture on the first pass gives the treatment team the best information from the start.
Image Guidance and Targeting
Hitting the right spot matters as much as choosing the right needle. Many biopsies are performed under real-time imaging, typically ultrasound or CT, so the operator can watch the needle enter the lesion. This is especially important for deep organs like the liver, lung, or pancreas, where a millimeter of misplacement can mean the difference between sampling tumor and sampling normal tissue.
Fusion imaging, which overlays ultrasound with a previously acquired CT or MRI scan in real time, has pushed accuracy further. In a study of focal liver lesions, fusion-guided biopsy achieved a diagnostic success rate of about 94%, significantly higher than conventional ultrasound-guided biopsy, which succeeded about 83% of the time. Lesions that were invisible on conventional ultrasound became visible and accessible with the fusion system, and the procedure was faster.
What Happens After the Needle Comes Out
Once a tissue sample reaches the pathology lab, it typically goes through fixation in formalin followed by embedding in paraffin wax. This combination preserves the tissue’s architecture and cellular shape well enough for thin slices to be cut, mounted on glass slides, and stained for microscopic examination.
For straightforward cases, a pathologist can identify the tissue type and whether cells look normal or abnormal using standard staining. But when a tumor looks unusual, or when a cancer has spread and the original organ is unknown, the lab turns to immunohistochemistry, a technique that uses antibodies to detect specific proteins on or inside cells. These protein markers act like fingerprints, helping pathologists classify tumor type and often trace a metastatic cancer back to its organ of origin. A meta-analysis found that immunohistochemistry correctly identified the tissue of origin in about 82% of blended primary and metastatic samples, and in about 66% of purely metastatic cancers.
Increasingly, biopsy tissue also undergoes molecular testing, where DNA or RNA is extracted and sequenced to look for mutations that might make the tumor vulnerable to targeted drugs. A study of small lung cancer biopsies found that 95% of specimens were adequate for full next-generation sequencing, yielding an average of nearly nine genomic alterations per tumor, roughly one of which was actionable for treatment.
When a Pathologist Is in the Room
One way to reduce the chance of an inadequate sample is to have a pathologist present during the procedure itself. This practice, called rapid on-site evaluation (ROSE), involves staining and examining a small portion of the aspirate or biopsy immediately, while the patient is still on the table. If the initial pass looks like it missed the lesion, the operator can adjust and try again on the spot.
A five-year audit of lung cancer specimens found that samples obtained with ROSE had a tissue adequacy rate above 95% for molecular testing requirements.
Whether ROSE actually improves diagnostic accuracy depends on the needle being used. A meta-analysis of pancreatic biopsies found that ROSE significantly boosted accuracy when older reverse-bevel needles were used but made no measurable difference with newer end-cutting needles, which retrieve higher-quality tissue cores on their own. As needle design improves, the added value of having a pathologist in the room may shrink for certain procedures, though many centers still consider it worthwhile for complex or hard-to-reach lesions.
Liquid Biopsies and Their Limits
The term “liquid biopsy” refers to analyzing a blood sample for tumor-derived material, most commonly fragments of tumor DNA circulating in the bloodstream, but also circulating tumor cells and tiny vesicles called exosomes. The appeal is obvious: a simple blood draw instead of a needle in your liver or lung. Liquid biopsy is already used clinically in some settings, particularly to monitor treatment response or detect new mutations when a tumor evolves during therapy.
But liquid biopsy is not yet a replacement for tissue biopsy when it comes to initial diagnosis or comprehensive molecular profiling. A study comparing tissue sequencing to blood-based sequencing in lung adenocarcinoma found that tissue testing had a sensitivity of about 95% for clinically relevant mutations, while blood-based testing caught only about 53%.
That does not mean liquid biopsy is useless. A large study of over 800 patients with advanced cancer found that in about 15% of cases, blood-based profiling identified treatment-relevant genetic changes that tissue biopsy had missed, and a matched therapy recommendation would not have been possible without those blood results. The reverse was also true: tissue profiling caught changes that blood testing missed in about 17% of patients. The two approaches are increasingly seen as complementary rather than competing, with tissue biopsy remaining the preferred first-line method when tissue is available, and liquid biopsy filling in the gaps when it is not.
For patients whose tumors cannot be safely biopsied, or who have too little tissue left from prior procedures, liquid biopsy using next-generation sequencing can reliably identify actionable mutations and help start personalized therapy without delay.
Complications and Safety
No biopsy is risk-free, though serious complications are uncommon for most procedures. The organ being sampled heavily determines what can go wrong. Lung biopsies carried out through the chest wall (transthoracic needle biopsies) have a well-documented complication profile: a large population-based study of nearly 17,000 patients found that about 26% experienced a complication within three days, overwhelmingly pneumothorax, which occurred in about 23% of cases. Of those who developed a pneumothorax, roughly a third needed a chest tube; the rest resolved on their own. Hemorrhage occurred in about 4% of patients, and air embolism was exceedingly rare at 0.02%.
Another concern, more theoretical than practical for most patients, is needle-tract seeding, the possibility that the needle drags tumor cells along its path as it exits the body. A single-institution study of kidney tumor biopsies found seeding in the needle tract in 6% of renal cell carcinoma cases, but these were overwhelmingly one particular subtype (papillary renal cell carcinoma, where the rate was 21%). None of those patients developed recurrence or metastasis related to the seeding. The mechanical force of the needle can displace cells and cause local bleeding that carries cells outward, but the clinical consequences appear to be minimal in most tumor types.
Patients with chronic obstructive pulmonary disease, those taking blood thinners, and those biopsied in an inpatient setting tend to face higher complication rates, particularly for lung procedures. Doctors weigh these factors when deciding whether a biopsy is worth the risk or whether imaging surveillance might be a reasonable alternative.
Pain, Anxiety, and What to Expect
For many patients, the anxiety surrounding a biopsy is at least as significant as the physical discomfort. A study comparing prostate biopsy approaches found that patients undergoing the transperineal route reported higher pain scores than those undergoing the transrectal route (about 3.9 versus 1.6 on a ten-point scale), though pain dropped to nearly zero immediately afterward. Anxiety levels were also significantly higher in the transperineal group, with about 71% reporting preprocedure anxiety compared to 45% in the transrectal group.
Techniques for managing biopsy-related anxiety and pain have expanded beyond standard local anesthesia. Buffering and warming the anesthetic solution can reduce the sting of injection. Non-pharmacological strategies, including relaxation techniques, music therapy, and virtual reality headsets that immerse the patient in a calming environment, have all been explored with varying degrees of success. Virtual reality in particular has gained traction across several medical fields as a distraction tool during procedures performed under local anesthesia.
Artificial Intelligence in Biopsy Analysis
AI is beginning to change how biopsy slides are read. Digital pathology systems that scan glass slides into high-resolution images allow algorithms to flag suspicious areas, classify tissue patterns, or suggest a diagnosis before a human pathologist reviews the case. A systematic review and meta-analysis of AI-based diagnostic tools in digital pathology reported a mean sensitivity of about 96% and a mean specificity of about 93% across studies.
In prostate biopsies specifically, a study of an AI-assisted system found that pathologists maintained their diagnostic accuracy (around 94-95%) while requesting about 20% fewer immunohistochemistry studies, about 40% fewer second opinions, and spending roughly 20% less time per slide. The AI did not replace the pathologist; it acted more like a pre-screening filter, allowing the human expert to focus attention where it mattered most.
These tools are still relatively new in clinical practice, and most are approved as decision-support aids rather than standalone diagnostic devices. But as digital slide scanners become standard in pathology departments, the infrastructure for AI-assisted biopsy interpretation is falling into place.
Biopsies Beyond Cancer
Although cancer diagnosis drives most of the public conversation about biopsies, tissue sampling plays a critical role in other areas of medicine. Kidney biopsy remains the gold standard for diagnosing and grading rejection episodes in transplant recipients. When a transplanted kidney starts showing signs of trouble, blood tests can raise the alarm, but only a biopsy can tell the clinician whether the immune system is attacking the organ, and if so, what type of rejection is occurring and how aggressively to treat it.
Emerging blood-based biomarkers may eventually detect transplant injury before it becomes clinically obvious, potentially reducing the need for repeated invasive biopsies. But for now, tissue examination remains the backbone of transplant diagnostics.
Liver biopsies are routinely used to stage fibrosis in chronic hepatitis or fatty liver disease. Muscle biopsies help diagnose inflammatory myopathies. Bone marrow biopsies are essential for evaluating blood cancers and unexplained blood count abnormalities. In each case, the logic is the same: looking at the tissue under a microscope reveals information that no blood test or scan can provide on its own.
Global Access and Equity
Advanced biopsy techniques and the molecular testing that follows them are not equally available everywhere. In high-income countries, it is increasingly routine for a lung cancer biopsy to be followed by next-generation sequencing, immunohistochemistry panels, and a molecular tumor board discussion that matches the patient to a targeted therapy. In low- and middle-income countries, the infrastructure for these steps is often limited or absent, creating diagnostic disparities that directly affect treatment options and outcomes.
This gap extends to liquid biopsy as well. While the technology is becoming widespread in tertiary care centers in wealthier nations, regulatory differences, lack of assay standardization, and the cost of commercial platforms put it out of reach for much of the world. Calls to decentralize liquid biopsy expertise to local pathology labs, rather than relying on centralized commercial services, aim to reduce these disparities and improve data sovereignty for institutions in underserved regions.
What Happens to Your Tissue Afterward
After a biopsy is analyzed and the diagnosis is made, the leftover tissue does not simply disappear. Most pathology departments archive formalin-fixed, paraffin-embedded tissue blocks indefinitely, both for potential future clinical use (if a patient’s cancer returns years later, comparing old and new tissue can be valuable) and, in many institutions, for research through biobanks.
The secondary use of patient tissue in cancer research raises consent questions that have not been fully resolved. Consent forms signed years or decades ago may not have anticipated the kinds of genomic analysis now possible on archived specimens. Institutions are grappling with how to balance the enormous research value of these tissue collections against evolving expectations around patient autonomy and data privacy. Practices vary widely, with some biobanks operating under broad consent models and others requiring re-consent for new types of analysis.